Analysts have been eager to weigh in on the Healthcare sector with new ratings on Travere Therapeutics (TVTX – Research Report), Humana (HUM – Research Report) and Merck & Company (MRK – Research Report).
Travere Therapeutics (TVTX)
Bank of America Securities analyst Greg Harrison maintained a Buy rating on Travere Therapeutics yesterday and set a price target of $21.00. The company’s shares closed last Wednesday at $5.45, close to its 52-week low of $5.25.
According to TipRanks.com, Harrison is a 2-star analyst with an average return of
Currently, the analyst consensus on Travere Therapeutics is a Moderate Buy with an average price target of $14.25, a 146.5% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $19.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Humana (HUM)
In a report released yesterday, Kevin Fischbeck from Bank of America Securities maintained a Hold rating on Humana, with a price target of $342.00. The company’s shares closed last Wednesday at $315.98, close to its 52-week low of $299.23.
According to TipRanks.com, Fischbeck is a 3-star analyst with an average return of
Humana has an analyst consensus of Moderate Buy, with a price target consensus of $364.44, representing an 8.8% upside. In a report issued on April 11, J.P. Morgan also maintained a Hold rating on the stock with a $332.00 price target.
Merck & Company (MRK)
Bank of America Securities analyst Geoff Meacham maintained a Buy rating on Merck & Company yesterday and set a price target of $135.00. The company’s shares closed last Wednesday at $127.00.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
Currently, the analyst consensus on Merck & Company is a Strong Buy with an average price target of $135.44, representing a 6.8% upside. In a report issued on April 18, Cantor Fitzgerald also maintained a Buy rating on the stock with a $135.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TVTX:
- Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Travere Therapeutics, CSL Vifor announce EC approval for Filspari
- Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
- Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
- Travere downgraded to Neutral at Guggenheim on smaller role in IgAN space
